glp 1 blindness risk GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes GLP-1 Drugs and Diabetic Eye

doi: 10.1002/oby.22653, 95

Severe or persistent symptoms with either medicine should be medically reviewed

The study should span longer than six years and eliminate unknowns, such as if the patients stopped taking semaglutide

10.1186/s12872-021-02030-5 2 BalestrieriM

Here we review published data from 24-h time-averaged HR monitoring in healthy individuals and subjects with type 2 diabetes mellitus (T2DM) treated with either short-acting GLP-1 RAs, lixisenatide or exenatide, or long-acting GLP-1 RAs, exenatide LAR, liraglutide, albiglutide, or dulaglutide (N = 1112

While some may argue about inflammation or sugar content, the primary issue is the ethanol, which is present in all three